kentucky glp-1 diarrhea class action gi obstruction law firm in louisiana gastrointestinal semaglutide diarrhea law firm glp-1 diarrhea class action in

The FDA also required changes to the labels to achieve a more uniform presentation of side effects and risk information for all of the drugs in the GLP-1 category, including adding or changing subsections for Acute Pancreatitis and Severe Gastrointestinal Adverse Reactions and revising the Patient Counseling section and Medication Guide. Some of the labels were also updated with post-marketing reports of hair loss (alopecia) and the neurological symptom of altered sense of touch, or dysethesia

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort

Train with purpose

Sleep disruption that compounds everything else

Additionally, these agents slow gastric emptying, which prolongs the sensation of fullness after meals and reduces appetite through effects on brain centres that regulate hunger

Safe GLP-1 therapy generally requires: Baseline metabolic laboratory testing Medication review Screening for thyroid and pancreatic history Ongoing clinical follow-up Lowering the dose does not eliminate contraindications